Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632827 · ClinicalTrials.gov registry record · Phase 2
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00632827 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 21 participants.
The verdict
NCT00632827, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
Interventions
- DRUG Gemcitabine
- DRUG Pegfilgrastim
- DRUG Granulocyte-colony stimulating factor (G-CSF)
- DRUG Navelbine
- DRUG Doxorubicin Hydrochloride Liposome Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-07-01 |
| Est. Completion | 2016-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00632827
The ClinicalTrials.gov registry entry for NCT00632827 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT00632827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00632827 about?
NCT00632827 is a clinical study titled "Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)". This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
What is the current status of trial NCT00632827?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-07-01. Estimated completion is 2016-06-23.
What interventions are being tested in trial NCT00632827?
The interventions under investigation include: Gemcitabine (DRUG), Pegfilgrastim (DRUG), Granulocyte-colony stimulating factor (G-CSF) (DRUG), Navelbine (DRUG), Doxorubicin Hydrochloride Liposome Injection (DRUG).
Who is sponsoring clinical trial NCT00632827?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.